WallStreetZenWallStreetZen

NASDAQ: AYTU
Aytu Biopharma Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for AYTU

Based on 1 analyst offering 12 month price targets for Aytu Biopharma Inc

Min Forecast
$14.50+571.3%
Avg Forecast
$14.50+571.3%
Max Forecast
$14.50+571.3%

Should I buy or sell AYTU stock?

Based on 1 analyst offering ratings for Aytu Biopharma Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their AYTU stock forecasts and price targets.

AYTU stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-06-11

1 of 1

Forecast return on equity

Is AYTU forecast to generate an efficient return?

Company
34.89%
Industry
9.37%
Market
147.87%
AYTU's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is AYTU forecast to generate an efficient return on assets?

Company
10.98%
Industry
16.6%
AYTU is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

AYTU earnings per share forecast

What is AYTU's earnings per share in the next 2 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$0.25
Avg 2 year Forecast
$1.14

AYTU revenue forecast

What is AYTU's revenue in the next 2 years based on estimates from 5 analysts?

Avg 1 year Forecast
$72.0M+27.28%
Avg 2 year Forecast
$96.4M+70.3%
AYTU's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

AYTU revenue growth forecast

How is AYTU forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
30.5%
Industry
12.48%
Market
16.51%
AYTU's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
AYTU's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

AYTU vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
AYTU$2.16$14.50+571.30%Buy
TXMD$2.11N/AN/A
RMTI$6.30$20.00+217.71%Buy
OPTH$4.79N/AN/A
KALA$0.75N/AN/A
View Top Pharmaceutical Stocks

Aytu Biopharma Stock Forecast FAQ

Is Aytu Biopharma Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: AYTU) stock is to Buy AYTU stock.

Out of 1 analyst, 0 (0%) are recommending AYTU as a Strong Buy, 1 (100%) are recommending AYTU as a Buy, 0 (0%) are recommending AYTU as a Hold, 0 (0%) are recommending AYTU as a Sell, and 0 (0%) are recommending AYTU as a Strong Sell.

If you're new to stock investing, here's how to buy Aytu Biopharma stock.

What is AYTU's earnings growth forecast for 2027-2028?

(NASDAQ: AYTU) Aytu Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 15.5%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 69.28%.

Aytu Biopharma's earnings in 2026 is -$34,055,000.On average, 5 Wall Street analysts forecast AYTU's earnings for 2027 to be -$2,682,229, with the lowest AYTU earnings forecast at -$4,207,418, and the highest AYTU earnings forecast at -$1,014,288.

In 2028, AYTU is forecast to generate $12,261,617 in earnings, with the lowest earnings forecast at $11,780,769 and the highest earnings forecast at $12,622,253.

What is AYTU's revenue growth forecast for 2027-2028?

(NASDAQ: AYTU) Aytu Biopharma's forecast annual revenue growth rate of 30.5% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 12.48%, and it is also forecast to beat the US market's average forecast revenue growth rate of 16.51%.

Aytu Biopharma's revenue in 2026 is $56,599,000.On average, 5 Wall Street analysts forecast AYTU's revenue for 2027 to be $773,241,771, with the lowest AYTU revenue forecast at $735,246,214, and the highest AYTU revenue forecast at $811,226,594.

In 2028, AYTU is forecast to generate $1,034,563,186 in revenue, with the lowest revenue forecast at $993,991,660 and the highest revenue forecast at $1,064,991,831.

What is AYTU's forecast return on assets (ROA) for 2027-2028?

(NASDAQ: AYTU) forecast ROA is 10.98%, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 16.6%.

What is AYTU's Price Target?

According to 1 Wall Street analyst that have issued a 1 year AYTU price target, the average AYTU price target is $14.50, with the highest AYTU stock price forecast at $14.50 and the lowest AYTU stock price forecast at $14.50.

The Wall Street analyst predicted that Aytu Biopharma's share price could reach $14.50 by Jun 11, 2027. The average Aytu Biopharma stock price prediction forecasts a potential upside of 571.3% from the current AYTU share price of $2.16.

What is AYTU's Earnings Per Share (EPS) forecast for 2027-2028?

(NASDAQ: AYTU) Aytu Biopharma's current Earnings Per Share (EPS) is -$4.55. On average, analysts forecast that AYTU's EPS will be -$0.25 for 2027, with the lowest EPS forecast at -$0.39, and the highest EPS forecast at -$0.09. In 2028, AYTU's EPS is forecast to hit $1.14 (min: $1.10, max: $1.18).

What is AYTU's forecast return on equity (ROE) for 2027-2028?

(NASDAQ: AYTU) forecast ROE is 34.89%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.